Chromatography ligand comprising domain C from Staphylococcus aureus protein A for antibody isolation

Patent metadata

Field	Value
Publication number	US-10213765-B2
Application number	US-201715603285-A
Country	US
Kind code	B2
Filing date	May 23, 2017
Priority date	Sep 29, 2006
Publication date	Feb 26, 2019
Grant date	Feb 26, 2019

Abstract

The present invention relates to a chromatography ligand, which comprises Domain C from Staphylococcus protein A (SpA), or a functional fragment or variant thereof. The chromatography ligand presents an advantageous capability of withstanding harsh cleaning in place (CIP) conditions, and is capable of binding Fab fragments of antibodies. The ligand may be provided with a terminal coupling group, such as arginine or cysteine, to facilitate its coupling to an insoluble carrier such as beads or a membrane. The invention also relates to a process of using the ligand in isolation of antibodies, and to a purification protocol which may include washing steps and/or regeneration with alkali.

First claim

What is claimed is:

1. A chromatography matrix comprising:
a solid support; and
a ligand coupled to the solid support, the ligand comprising at least two polypeptides,
wherein the amino acid sequence of each polypeptide comprises at least 55 contiguous amino acids of a modified SEQ ID NO. 1, and
wherein the modified SEQ ID NO. 1 has an alanine (A) instead of glycine (G) at a position corresponding to position 29 of SEQ ID NO. 1.

2. The chromatography matrix of claim 1 , wherein the ligand comprises 2-8 of the polypeptides, optionally coupled via linker segments.

3. The chromatography matrix of claim 1 , wherein the chromatography matrix has retained at least 95% of its original binding capacity after 5 hours incubation in 0.5 M NaOH.

4. The chromatography matrix of claim 1 , wherein the ligand is capable of binding to the Fab part of an antibody.

5. The chromatography matrix of claim 1 , wherein the ligand comprises a terminal coupling group comprising at least one nitrogen and/or sulfur atom(s).

6. The chromatography matrix of claim 5 , wherein the terminal group comprises arginine or cysteine.

7. The chromatography matrix of claim 1 , wherein the ligand is coupled to the solid support via thioether bonds.

8. The chromatography matrix of claim 1 , wherein the ligand further comprises one or more other alkaline-stable protein-based units.

9. The chromatography matrix of claim 1 , wherein the solid support is a polysaccharide.

10. The chromatography matrix of claim 1 , wherein the solid support is comprised of substantially spherical particles.

11. The chromatography matrix of claim 1 , wherein the solid support is porous.

12. The chromatography matrix of claim 1 , wherein the ligand comprises an amino acid sequence that comprises 2-8 of the polypeptides.

13. The chromatography matrix of claim 1 , wherein the solid support comprises two or more ligands.

14. A chromatography matrix comprising:
a solid support; and
a ligand coupled to the solid support, the ligand comprising at least two polypeptides,
wherein the amino acid sequence of each polypeptide comprises at least 55 amino acids in alignment with SEQ ID NO. 1, and
wherein each polypeptide has an alanine (A) instead of glycine (G) at a position corresponding to position 29 of SEQ ID NO. 1.

15. The chromatography matrix of claim 14 , wherein the ligand comprises 2-8 of the polypeptides, optionally coupled via linker segments.

16. The chromatography matrix of claim 14 , wherein the chromatography matrix has retained at least 95% of its original binding capacity after 5 hours incubation in 0.5 M NaOH.

17. The chromatography matrix of claim 14 , wherein the ligand is capable of binding to the Fab part of an antibody.

18. The chromatography matrix of claim 14 , wherein the ligand comprises a terminal coupling group comprising at least one nitrogen and/or sulfur atom(s).

19. The chromatography matrix of claim 18 , wherein the terminal group comprises arginine or cysteine.

20. The chromatography matrix of claim 14 , wherein the ligand is coupled to the solid support via thioether bonds.

21. The chromatography matrix of claim 14 , wherein the ligand further comprises one or more other alkaline-stable protein-based units.

22. The chromatography matrix of claim 14 , wherein the solid support is a polysaccharide.

23. The chromatography matrix of claim 14 , wherein the solid support is comprised of substantially spherical particles.

24. The chromatography matrix of claim 14 , wherein the solid support is porous.

25. The chromatography matrix of claim 14 , wherein the ligand comprises an amino acid sequence that comprises 2-8 of the polypeptides.

26. The chromatography matrix of claim 14 , wherein the solid support comprises two or more ligands.

Assignees

• Ge Healthcare Bioprocess R&D Ab
• GE Healthcare Bioprocess R&D

Inventors

• Hall Martin
• Larsson Sture
• Muranyi Andreas
• Rodrigo Gustav
• Zou Jinyu
• Aberg Per-Mikael

Classifications

• C07K2317/55

  Fab or Fab' · CPC title

• B01J20/286

  Phases chemically bonded to a substrate, e.g. to silica or to polymers · CPC title

• B01J20/24 Primary

  Naturally occurring macromolecular compounds, e.g. humic acids or their derivatives · CPC title

• B01D15/3809 Primary

  of the antigen-antibody type, e.g. protein A, G or L chromatography · CPC title

• B01J20/3212

  consisting of a polymer obtained by reactions otherwise than involving only carbon to carbon unsaturated bonds · CPC title